Chart: Grassley Wants Update On 510(k) Modifications Guidance
This article was originally published in The Gray Sheet
Executive Summary
Sen. Chuck Grassley, R-Iowa, wants a status report on FDA's revised guidelines for helping firms decide whether or not to submit a new 510(k) after making changes to an already cleared device, according to a Feb. 16 letter to FDA Commissioner Margaret Hamburg.
You may also be interested in...
FDA Hints At Possible 510(k) Tweaks At Public Meeting
FDA is considering changing how predicate devices are selected for 510(k) submissions and beefing up its post-market authorities for 510(k)-cleared products, agency reps suggested at a Feb. 18 public meeting
FDA Policy For Device Modifications Faces Mounting Scrutiny
Legislators looking for weak spots in FDA's device pre-market review program have honed in on a perceived loophole that allows firms to change existing 510(k) products without notifying FDA
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”